NIH Phase Ib/II DLBCL drug combo trial reports 34% complete response
A five-drug combination therapy targeted multiple molecular pathways diffuse large B-cell lymphoma (DLBCL) tumours use to survive.
Oncology Clinical Trial Trends in the US
Tackling trial diversity in a biased clinical development landscape
Genentech experts call for multiple strategies to diversify clinical trials
US West Coast oncology clinical trials lead in diversity
FDA questions efficacy of Amgen’s Lumakras in lung cancer trial
Leap enrols first subject in Phase II colorectal cancer antibody trial
FDA grants IND clearance for Phase I trials of Phanes’ cancer antibody
Janux doses first subject in Phase I prostate cancer therapy trial
